查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1771079

促红血球生成素刺激剂市场－全球产业规模、份额、趋势、机会和预测（按类型、应用、地区和竞争细分，2020-2030 年）

Erythropoietin Stimulating Agents Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球促红血球生成素刺激剂市值为 74.5 亿美元，预计到 2030 年将以 8.14% 的复合年增长率成长。促红血球生成素刺激剂 (ESA) 是促红血球生成素的合成形式，促红血球生成素是一种由肾臟自然产生的糖蛋白激素，可调节骨髓中的红血球生成。这些药物广泛用于治疗与慢性肾臟病 (CKD)、癌症治疗、HIV/AIDS 以及红血球计数低的外科手术相关的贫血。全球贫血盛行率不断上升，尤其是在孕妇、儿童和慢性病患者等弱势群体中，这推动了对 ESA 疗法的需求。根据 WHO 2025，贫血仍然是一个重大的全球健康问题，对低收入和农村人口的影响尤其严重。此外，全球人口老化更容易引发贫血，预计这将推动红血球生成素 (ESA) 的使用量持续成长。 ESA 在改善患者生活品质方面发挥着至关重要的作用，使其成为治疗与贫血相关的慢性和急性疾病的重要组成部分。

市场概览
预测期 2026-2030
2024年市场规模 74.5亿美元
2030年市场规模 118.2亿美元
2025-2030 年复合年增长率 8.14%
成长最快的领域 依泊汀阿尔法
最大的市场 北美洲

关键市场驱动因素

肿瘤学进展

主要市场挑战

专利到期

主要市场趋势

转向 Epoetin 生物类似药

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：COVID-19 对全球饲料植物性市场的影响

第五章：顾客之声

第六章：全球促红血球生成素刺激剂市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 按类型（依泊汀阿尔法、依泊汀β、达贝泊汀阿尔法及其他类型）
    • 依应用（癌症、肾臟疾病、抗病毒治疗、神经疾病和其他应用）
    • 按地区
    • 按公司分类（2024）
  • 市场地图

第七章：亚太地区促红血球生成素刺激剂市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 澳洲
    • 日本
    • 韩国

第八章：欧洲促红血球生成素刺激剂市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 法国
    • 德国
    • 西班牙
    • 义大利
    • 英国

第九章：北美促红血球生成素刺激剂市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第十章：南美洲促红血球生成素刺激剂市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 11 章：中东和非洲促红血球生成素刺激剂市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 12 章：市场动态

  • 驱动程式
  • 挑战

第十三章：市场趋势与发展

  • 最新动态
  • 产品发布
  • 併购

第 14 章：全球促红血球生成素刺激剂市场：SWOT 分析

第 15 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 16 章： 大环境分析

第 17 章：竞争格局

  • Amgen Inc.
  • Biocon Limited
  • Celltrion Inc.
  • F. Hoffmann-La Roche Ltd
  • Intas Pharmaceuticals Ltd
  • Johnson and Johnson
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd
  • Thermo Fisher Scientific
  • LG Lifesciences, Ltd
  • Novartis AG(Sandoz)
  • Panacea Biotec Ltd

第 18 章：策略建议

第19章调查会社について・免责事项

简介目录
Product Code: 16145

The Global Erythropoietin Stimulating Agents Market was valued at USD 7.45 billion in 2024 and is projected to grow at a CAGR of 8.14% through 2030. Erythropoietin Stimulating Agents (ESAs) are synthetic forms of erythropoietin, a glycoprotein hormone naturally produced by the kidneys that regulates red blood cell production in the bone marrow. These agents are widely used to treat anemia associated with chronic kidney disease (CKD), cancer therapies, HIV/AIDS, and surgical procedures where red blood cell counts are low. The increasing global prevalence of anemia, especially in vulnerable populations such as pregnant women, children, and individuals with chronic illnesses, is driving demand for ESA therapies. According to WHO 2025, anemia remains a significant global health issue, disproportionately affecting low-income and rural populations. Furthermore, the aging global population, which is more susceptible to conditions leading to anemia, is expected to contribute to sustained growth in ESA usage. ESAs play a crucial role in improving patient quality of life, making them a vital component in managing chronic and acute medical conditions associated with anemia.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 7.45 Billion
Market Size 2030USD 11.82 Billion
CAGR 2025-20308.14%
Fastest Growing SegmentEpoetin Alfa
Largest MarketNorth America

Key Market Drivers

Advancements in Oncology

The rising incidence of chemotherapy-induced anemia (CIA) has led to a growing reliance on ESAs such as Epoetin Alfa and Darbepoetin Alfa to mitigate fatigue and enhance patient well-being during cancer treatment. Recent advancements in oncology have introduced more effective and targeted therapies, which may reduce the severity of anemia but also require precise supportive treatments like ESAs. Oncology research has also improved the understanding of ESA safety profiles, enabling better identification of patient subgroups that can safely benefit from these therapies. Personalized medicine and oncogenomics have further contributed to tailored ESA administration based on genetic markers and cancer types, optimizing outcomes while minimizing adverse effects. These developments have bolstered ESA integration into oncology protocols, enhancing their clinical utility and market demand.

Key Market Challenges

Patent Expirations

Patent expirations pose a significant challenge to the growth and profitability of the ESA market. As patents for key ESA drugs expire, it paves the way for the introduction of generic and biosimilar versions, intensifying market competition and driving down prices. These lower-cost alternatives often capture a substantial market share, particularly in price-sensitive healthcare systems. While this may improve patient access, it also leads to revenue declines for original ESA manufacturers. The market may become fragmented, with multiple players offering comparable products, increasing pricing pressures and reducing the incentive for continued innovation. Manufacturers are compelled to revise their pricing and market strategies to remain competitive. Although cost savings benefit healthcare systems, the shift can create challenges in ensuring consistent quality, safety, and patient trust in biosimilar products.

Key Market Trends

Shift Toward Epoetin Biosimilars

The emergence and growing acceptance of Epoetin biosimilars are significantly transforming the ESA market landscape. Biosimilars, developed to be highly similar to already approved biologics, offer equivalent safety and efficacy at a lower cost. This price advantage makes biosimilars appealing to healthcare systems and providers aiming to reduce expenditure without compromising treatment quality. The availability of Epoetin biosimilars has increased competition, expanded patient access, and driven broader adoption of ESA therapies, especially in budget-constrained regions. Regulatory approvals from agencies like the FDA and EMA have reinforced confidence in biosimilars, encouraging uptake among physicians and patients. As real-world evidence continues to support their reliability, the shift toward biosimilars is expected to further strengthen, offering substantial cost savings while maintaining treatment standards in managing anemia.

Report Scope:

In this report, the Global Erythropoietin Stimulating Agents Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Erythropoietin Stimulating Agents Market, By Type:

  • Epoetin Alfa
  • Epoetin Beta
  • Darbepoetin Alfa
  • Other Types

Erythropoietin Stimulating Agents Market, By Application:

  • Cancer
  • Renal Disorders
  • Anti-retroviral Treatment
  • Neural Diseases
  • Other Applications

Erythropoietin Stimulating Agents Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Australia
    • Japan
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Erythropoietin Stimulating Agents Market.

Available Customizations:

Global Erythropoietin Stimulating Agents Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Impact of COVID-19 on Global Feed Phytogenic Market

5. Voice of Customer

6. Global Erythropoietin Stimulating Agents Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type (Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa, And Other Types)
    • 6.2.2. By Application (Cancer, Renal Disorders, Anti-retroviral Treatment, Neural Diseases, and Other Applications)
    • 6.2.3. By Region
    • 6.2.4. By Company (2024)
  • 6.3. Market Map

7. Asia Pacific Erythropoietin Stimulating Agents Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Asia Pacific: Country Analysis
    • 7.3.1. China Erythropoietin Stimulating Agents Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
    • 7.3.2. India Erythropoietin Stimulating Agents Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
    • 7.3.3. Australia Erythropoietin Stimulating Agents Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
    • 7.3.4. Japan Erythropoietin Stimulating Agents Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
    • 7.3.5. South Korea Erythropoietin Stimulating Agents Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application

8. Europe Erythropoietin Stimulating Agents Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Erythropoietin Stimulating Agents Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
    • 8.3.2. Germany Erythropoietin Stimulating Agents Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Spain Erythropoietin Stimulating Agents Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
    • 8.3.4. Italy Erythropoietin Stimulating Agents Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
    • 8.3.5. United Kingdom Erythropoietin Stimulating Agents Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application

9. North America Erythropoietin Stimulating Agents Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Erythropoietin Stimulating Agents Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
    • 9.3.2. Mexico Erythropoietin Stimulating Agents Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
    • 9.3.3. Canada Erythropoietin Stimulating Agents Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application

10. South America Erythropoietin Stimulating Agents Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Erythropoietin Stimulating Agents Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Argentina Erythropoietin Stimulating Agents Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
    • 10.3.3. Colombia Erythropoietin Stimulating Agents Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application

11. Middle East and Africa Erythropoietin Stimulating Agents Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type
    • 11.2.2. By Application
    • 11.2.3. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Erythropoietin Stimulating Agents Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Type
        • 11.3.1.2.2. By Application
    • 11.3.2. Saudi Arabia Erythropoietin Stimulating Agents Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Type
        • 11.3.2.2.2. By Application
    • 11.3.3. UAE Erythropoietin Stimulating Agents Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Type
        • 11.3.3.2.2. By Application

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Product Launches
  • 13.3. Mergers & Acquisitions

14. Global Erythropoietin Stimulating Agents Market: SWOT Analysis

15. Porter's Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Product

16. PESTLE Analysis

17. Competitive Landscape

  • 17.1. Amgen Inc.
    • 17.1.1. Business Overview
    • 17.1.2. Company Snapshot
    • 17.1.3. Products & Services
    • 17.1.4. Financials (In case of listed companies)
    • 17.1.5. Recent Developments
    • 17.1.6. SWOT Analysis
  • 17.2. Biocon Limited
  • 17.3. Celltrion Inc.
  • 17.4. F. Hoffmann-La Roche Ltd
  • 17.5. Intas Pharmaceuticals Ltd
  • 17.6. Johnson and Johnson
  • 17.7. Pfizer Inc.
  • 17.8. Teva Pharmaceutical Industries Ltd
  • 17.9. Thermo Fisher Scientific
  • 17.10. LG Lifesciences, Ltd
  • 17.11. Novartis AG(Sandoz)
  • 17.12. Panacea Biotec Ltd

18. Strategic Recommendations

19. About Us & Disclaimer